These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 29339396)

  • 21. New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae.
    Brennan-Krohn T; Manetsch R; O'Doherty GA; Kirby JE
    Transl Res; 2020 Jun; 220():14-32. PubMed ID: 32201344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotics in the clinical pipeline in October 2019.
    Butler MS; Paterson DL
    J Antibiot (Tokyo); 2020 Jun; 73(6):329-364. PubMed ID: 32152527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apralogs: Apramycin 5-
    Quirke JCK; Rajasekaran P; Sarpe VA; Sonousi A; Osinnii I; Gysin M; Haldimann K; Fang QJ; Shcherbakov D; Hobbie SN; Sha SH; Schacht J; Vasella A; Böttger EC; Crich D
    J Am Chem Soc; 2020 Jan; 142(1):530-544. PubMed ID: 31790244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Whole-Cell Screen for Adjunctive and Direct Antimicrobials Active against Carbapenem-Resistant Enterobacteriaceae.
    Smith KP; Dowgiallo MG; Chiaraviglio L; Parvatkar P; Kim C; Manetsch R; Kirby JE
    SLAS Discov; 2019 Sep; 24(8):842-853. PubMed ID: 31268804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of apramycin against spectinomycin-resistant and -susceptible strains of Neisseria gonorrhoeae.
    Riedel S; Vijayakumar D; Berg G; Kang AD; Smith KP; Kirby JE
    J Antimicrob Chemother; 2019 May; 74(5):1311-1316. PubMed ID: 30689929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Treatment Options against Carbapenem-Resistant
    Isler B; Doi Y; Bonomo RA; Paterson DL
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates.
    Truelson KA; Brennan-Krohn T; Smith KP; Kirby JE
    Diagn Microbiol Infect Dis; 2018 Oct; 92(2):168-171. PubMed ID: 29934071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance.
    Durante-Mangoni E; Zarrilli R
    Future Microbiol; 2011 Apr; 6(4):407-22. PubMed ID: 21526942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acinetobacter baumannii: an emerging multidrug-resistant threat.
    Gootz TD; Marra A
    Expert Rev Anti Infect Ther; 2008 Jun; 6(3):309-25. PubMed ID: 18588496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model.
    Kang AD; Smith KP; Berg AH; Truelson KA; Eliopoulos GM; McCoy C; Kirby JE
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29339396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Invitro Apramycin Activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.
    Kang AD; Smith KP; Eliopoulos GM; Berg AH; McCoy C; Kirby JE
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):188-191. PubMed ID: 28341099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii.
    Juhas M; Widlake E; Teo J; Huseby DL; Tyrrell JM; Polikanov YS; Ercan O; Petersson A; Cao S; Aboklaish AF; Rominski A; Crich D; Böttger EC; Walsh TR; Hughes D; Hobbie SN
    J Antimicrob Chemother; 2019 Apr; 74(4):944-952. PubMed ID: 30629184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and bioevaluation of SRI-12742 as an antimicrobial agent against multidrug-resistant Acinetobacter baumannii.
    Shukla M; Soni I; Matsuyama K; Tran T; Tanga M; Gong L; Chopra S
    Int J Antimicrob Agents; 2018 Jul; 52(1):22-27. PubMed ID: 29501820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model.
    Stainton SM; Monogue ML; Tsuji M; Yamano Y; Echols R; Nicolau DP
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30420477
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Nakamura R; Ito-Horiyama T; Takemura M; Toba S; Matsumoto S; Ikehara T; Tsuji M; Sato T; Yamano Y
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262762
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Hu Y; Liu L; Zhang X; Feng Y; Zong Z
    Front Microbiol; 2017; 8():2275. PubMed ID: 29250040
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.